Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

Inclusion Criteria: * male * non smoking for at least 12 months * BMI equal to or less than 28 * no clinically significant abnormalities * FVC and FEV1 equal to or more than 80% * willing to participate and to sign informed consent form Exclusion Criteria: * positive results for insulin antibodies at screening * history of substance abuse or dependency within last 5 years * positive screening test for substance abuse * positive blood test for HIV, hepatitis B or hepatitis C antibody * fasting blood glucose of more than 126mg/dl * any existing medical conditions which might interfere with absoprtion, distribution, metabolism or excretion of study medication * history of bronchospastic disease(asthma), tachycardia, migraine headache, hypoglycemic episodes, jaundice, liver diseases, arterial hemorrhaging, severe hypertension or hypotension, cardiac abnormality, renal disease, allergies, unresolved psychiatric illness, drug-induced myopathy or any other clinically significant abnormality * has received investigational medications within 21 days prior to receiving the first dose of study medication * has taken or used any prescription medications within 21 days prior to receiving the first dose of study medication * has taken or used any OTC medications,vitamins or herbal and/or nutritional supplements within 10 days days prior to receiving the first dose of study medication * health that may be adversely affected by procedures or medications used in the study * unwillingness or inability to understand or to follow required study restrictions and procedures